Intramuscular transplantation of macroencapsulated islets for type 1 diabetes mellitus in mice

doi:10.3969/j.issn.2095-4344.2013.25.011

Abstract

Abstract:

BACKGROUND: Alginate-barium chloride microbeads confer immune isolation and prevent graft rejection in preliminary experiments.
OBJECTIVE: To assess the role of alginate- barium chloride microbead encapsulation in the treatment of type 1 diabetes mellitus in mice.
METHODS: The single islet cell group was isolated from the pancreas of Sprague-Dawley rats and purified. And cells were encapsulated into alginate-barium chloride microbeads. Type 1 diabetes mellitus was induced with streptozotocin into C57BL/6 mice via intraperitoneal injection, and randomly divided into four groups. The pure islets encapsulated in alginate-barium chloride microbeads were transplanted into the biceps femoris in the mice with type 1 diabetes mellitus, as experimental group. The pure islets were transplanted into diabetic recipients at biceps femoris, as control group. Normal C57BL/6 mice were injected with saline into biceps femoris, as normal control group. Diabetic C57BL/6 mice were injected with saline into biceps femoris, as diabetes control group. Then the blood glucose levels and macroencapsulated islets at the transplantation site were observed.
RESULTS AND CONCLUSION: After isolation and purification, (905.4±34.5) islets per mouse were obtained and possessed excellent activity. Duration of normal blood glucose after operation in experimental group was approximately 6.3 days. The islet graft survival duration was longer than 30 days. The blood glucose levels in control group were not recovered to normal, and the islet graft survival duration was 4 days. The glucose-lowering rate in experimental group was significantly faster than that in control group and diabetes control group (P < 0.05). Experimental findings indicate that, islets encapsulated in alginate-barium chloride microbeads could survive in the muscles and treat type 1 diabetes mellitus.

Key words: biomaterials, biomaterials and controlled drug release, islet xenograft, alginate-barium chloride, microbead, transplantation, type 1 diabetes mellitus, blood glucose, C57BL/6 mice, National Natural Science Foundation of China

CLC Number:

R318

Li Hui, Fu Hong-xing, Zhu Yan-lin, Li Xiao-kun. Intramuscular transplantation of macroencapsulated islets for type 1 diabetes mellitus in mice[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(25): 4637-4643.

Figures/Tables 3

References

[1] Shapiro AM,Lakey JR,Ryan EA,et al.Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med.2000;343(4): 230-238.

[2] Shapiro AM,Ricordi C,Hering B,et al.International trial of the Edmonton protocol for islet transplantation.N Engl J Med. 2006;355(13): 1318-1330.

[3] Ryan EA,Paty BW,Senior PA,et al.Five-year follow-up after clinical islet transplantation. Diabetes.2005;54(7): 2060-2069.

[4] Ricordi C,Strom TB.Clinical islet transplantation: advances and immunological challenges.Nat Rev Immunol.2004;(4): 259-268.

[5] Tokodai K,Goto M,Inagaki A,et al.C5a-inhibitory peptide combined with gabexate mesilate prevents the instant blood-mediated inflammatory reaction in a rat model of islet transplantation. Transplant Proc. 2010;42(6):2102-2103.

[6] Ngoc PK,Phuc PV,Nhung TH,et al.Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells.Human Cell.2011;24(2):86-95.

[7] Vériter S,Mergen J,Goebbels RM,et al.In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation. Tissue Eng Part A.2010; 16(5):1503-1512.

[8] Dufrane D,Goebbels RM,Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 2010;90(10): 1054-1062.

[9] Lim F,Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science.1980;210(4472): 908-910.

[10] Lanza RP,Hayes JL,Chick WL.Encapsulated cell technology. Nat Biotech. 1996;14(9): 1107-1111.

[11] O’Sullivan ES,Vegas A,Anderson DG,et al.Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocrine Reviews.2011;32(6): 827-844.

[12] Uonaga T,Toyoda K,Okitsu T,et al.FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model. Islets.2010;2(4):247-251.

[13] Vergani A,D'Addio F,Jurewicz M,et al.A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.Diabetes.2010;59(9):2253-2264.

[14] Xu YY,Fu HX,Wang ZM,et al.Zhongguo Xiufu Chongjian Waike Zazhi.2010;24(4):406-409.徐艳艳,傅红兴,王浙明,等. 大鼠胰岛分离纯化技术的改良及活性研究[J]. 中国修复重建外科杂志,2010,24(4):406-409.

[15] Hu XP,Ding YS,Qian TL.Zhongguo Dangdai Yiyao.2012; 19(14): 27-30.胡先平,丁亚山,钱滔来.消化时间对大鼠胰岛分离纯化产量的影响[J].中国当代医药,2012,19(14):27-30.

[16] Wang YF,Wang HL,Luo SQ.Zhongguo Zhuzhi Gongcheng Yanjiu Yu Linchuang Kangfu.2011,15(44):8247-8250. 王雁飞,王洪林,罗诗樵.糖尿病小鼠理想的胰岛移植部位[J].中国组织工程研究与临床康复,2011,15(44):8247-8250.

[17] Vaithilingam V,Oberholzer J,Guillemin GJ,et al.The humanized NOD/SCID mouse as a preclinical model to study the fate of encapsulated human islets.Rev Diabet Stud.2010; 7(1):62-73.

[18] Christoffersson G,Henriksnäs J,Johansson L,et al.Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes.2010;59(10):2569-2578.

[19] Korsgren O,Nilsson B,Berme C,et al.Current status of clinical islet transplantation.Transplantation.2005;79(10):1289-1293.

[20] Rafael E,Tibell A,Ryden M,et al.Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up.Am J Transplant.2008;8:458-462.

[21] Zhang SL,Jiang ZS,Xing WJ,et al.Zhonghua Qiguan Yizhi Zazhi.1998;19(1):45-47.张胜兰,姜兆顺,邢万佳,等.改良的微囊化新生猪胰岛细胞移植治疗I型糖尿病八例报告[J].中华器官移植杂志,1998,19(1): 45-47.

[22] Qiou LY. Dongbei Nongye Daxue.2007: 19.邱丽媛.肝细胞包裹用微囊材料的研制及其治疗大鼠肝衰竭模型的实验研究[D].东北农业大学,2007: 19.

[23] Li CH,XueYL,LuoY,et al.Zhongguo Mianyixue Zazhi.2000; 16(5):259-261.李崇辉,薛毅珑,罗芸,等.APA 微囊对免疫细胞和细胞因子隔离效应的研究[J].中国免疫学杂志,2000,16(5):259-261.

[24] Dufrane D,van Steenberghe M,Goebbels RM,et al.The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats. Biomaterials. 2006;27(17):3201.

[25] Dufrane D,Goebbels RM,Saliez A,et al.Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: Proof of concept. Transplantation.2006;81:1345.

[26] Orive G,Hernández RM,Rodríguez Gascón A，et al.Drug delivery in biotechnology: present and future. Curr Opin Biotechnol.2003;14(6): 659-664.

[27] Chen ET,Yang XJ,Ye P, et al. Zhongguo Zhuzhi Gongcheng Yanjiu yu Linchuang Kangfu.2009;13(3):561-565.陈儿同,杨晓昀,叶萍,等.微囊胰岛移植的实验研究进展[J].中国组织工程研究与临床康复,2009,13(3):561-565.

[28] Sakata N,Sumi S,Yoshimatsu G,et al.Encapsulated islets transplantation: Past, present and future.World J Gastrointest Pathophysiol.2012;3(1): 19-26.